Merck's Keytruda wins FDA 'breakthrough' tag in colorectal cancer; Allergan nabs bowel drug rights in Europe;

> Merck & Co. ($MRK) won the FDA's breakthrough designation for its immuno-oncology therapy Keytruda in colorectal cancer; the drug is already approved to treat melanoma and lung cancer. Release

> Allergan ($AGN) bought the rights to Constella (linaclotide) in 40-plus countries, including major European markets, from Spain's Almirall; the drug is sold as Linzess in the U.S. Report

> New blockbuster drugs will drive big growth in the multiple myeloma market, GlobalData says, to $22.4 billion in sales by 2023, up from $8.9 billion in 2014. Report

> GlaxoSmithKline ($GSK), Roche ($RHHBY) and Sanofi ($SNY) all have major investor presentations this week, highlighting their R&D pipelines, and, in Sanofi's case, a new strategy from its new CEO, Olivier Brandicourt. Report

> Eisai said it's presenting data from an Asian Fycompa study in patients with difficult-to-treat partial-onset seizures, in which the drug topped placebo at cutting the frequency of seizures. Release

And Finally... The Novartis Foundation and its partners launched a hypertension screening effort in Ghana as part of a two-year test of an "innovative healthcare model" designed to control high blood pressure. Release

Suggested Articles

BMS' Opdivo and Yervoy only just won their first approval in previously untreated metastatic NSCLC, but the pair is already making it two.

Takeda’s Alunbrig has arrived in previously untreated, ALK-positive NSCLC. But there’s plenty of competition waiting to greet it at the door.

Sanofi and Regeneron's blockbuster Dupixent is eyeing an approval in eosinophilic esophagitis after cutting patients' difficulty breathing.